CDMO List for Regenerative Medicine, Cell Therapy, and Gene Therapy

This CDMO list has been compiled by the Forum for Innovative Regenerative Medicine (FIRM), in collaboration with the Ministry of Economy, Trade and Industry (METI), with the aim of addressing challenges in the manufacturing sector related to regenerative medicine, cell therapy, and gene therapy. By facilitating partnerships between academia and drug discovery startups—the key drivers of therapeutic innovation—and contract development and manufacturing organizations (CDMOs), this initiative seeks to promote the accumulation of domestic expertise in manufacturing process development and, ultimately, strengthen Japan’s drug discovery capabilities.
Survey Period: December 2024 – February 2025
Survey Method: Questionnaire conducted by a research agency. The information presented is based on responses provided directly by each participating company.
This list will be updated periodically.
If your company meets the criteria outlined below and wishes to be included, please contact us at: info@firm.or.jp
The companies listed in this table are CDMO companies (in the fields of cell therapy, ex vivo gene therapy, viral vectors, plasmids, and mRNA) that meet the following criteria:
・They are legally registered in Japan and have manufacturing facilities located within the country.
・They either:
1.Hold a manufacturing license for regenerative medicine products or for specified cell-processed products, or
2.Have publicly announced a manufacturing partnership with a CDMO company that holds one of the above-mentioned licenses.
Please note that this list may be referenced in the application guidelines for projects under the Japan Agency for Medical Research and Development (AMED), specifically those administered by METI, such as the "Project for the Development of Fundamental Technologies for the Industrialization of Regenerative Medicine and Gene Therapy." This includes support for manufacturing process development for drug discovery seeds aimed at regenerative medicine products.

Last Updated: Sep 1, 2025

Download

CDMO Companies with Regenerative Cell Therapy & Gene Therapy Manufacturing Facilities in Japan	CDMO Business Information (Max. 2 links per company)	ATMPs Manufacturable at Domestic Contract Manufacturing Facilities				ATMP Manufacturing License under Japan's Pharmaceuticals and Medical Devices Act (PMD Act)	Manufacturing License for Specific Cell-Processed Products under Japan's Act on the Safety of Regenerative Medicine	Biopharmaceutical Manufacturing Operations for Vaccine Production Capacity Enhancement	Partnership Status
	CDMO Business Information (Max. 2 links per company)	Cell Therapeutics (including ex vivo gene therapy)	Viral Vectors (AAV, LV, etc.)	Plasmid DNA	mRNA				Partnership Status
AGC Inc./AGC Biologics	WEB SITE	Under construction		✓	Under construction			✓	MEDINET Co., Ltd.
ARCALIS, Inc.	WEB SITE WEB SITE				✓ / Facilities under construction			✓
Cell Resources Corporation	CDMO Business Information	✓ / Facilities under construction					✓
CellSeed Inc.	WEB SITE CDMO Business Information	✓				✓	✓
Cyto-Facto Inc.	WEB SITE CDMO Business Information	✓ / Facilities under construction	Under construction			✓
FUJIFILM Toyama Chemical Co., Ltd.	WEB SITE CDMO Business Information				✓			✓
H.U.Cells, Inc.	WEB SITE CDMO Business Information	✓					✓		H.U. Group Holdings, Inc.
ID Pharma Co., Ltd	WEB SITE WEB SITE	✓ / Facilities under construction	✓ / Facilities under construction			✓	✓
Interstem Co., Ltd.	WEB SITE	✓					✓		We are processing adipose-derived mesenchymal stromal cells in collaboration with Rohto Pharmaceutical.
Japan Tissue Engineering Co., Ltd. (J-TEC)	WEB SITE CDMO Business Information	✓				✓	✓		Teijin Limited, J-TEC, Mitsui Fudosan Co., Ltd. and the National Cancer Center (NCC) have established a regenerative medicine platform in Japan. Overseas, Teijin and J-TEC have entered into a Letter of Intent for a global strategic collaboration with Resilience US, Inc. (Resilience) .
JCR Pharmaceuticals Co., Ltd.	WEB SITE	Under construction	Under construction			✓		✓
Kohjin Bio Co., Ltd.	CDMO Business Information	✓ / Facilities under construction					✓
MEDINET Co., Ltd.	WEB SITE CDMO Business Information	✓				✓	✓		AGC Inc.
MediRidge Co.,Ltd.	WEB SITE	✓	✓	✓ / Facilities under construction	✓				MediRidge has agreement with Teijin Regenet Co., Ltd. to supply plasmid DNA.
MicroBiopharm Japan Co., Ltd.	WEB SITE WEB SITE		✓ / Facilities under construction	✓ / Facilities under construction
Minaris Advanced Therapies Co., Ltd.	WEB SITE CDMO Business Information	✓ / Facilities under construction				✓			Alfresa Holdings Corporation, Cell Resources Corporation, VectorBuilder Inc., TFBS Bioscience Inc.、Myoridge Co. Ltd., Cryoport Systems, LLC, Locus Cell Co., Ltd., and Cell Tech Innovation Venture Studio Co., Ltd.
Nikon CeLL innovation Co., Ltd.	WEB SITE CDMO Business Information	✓ / Facilities under construction				✓			Lonza
PharmaBio Corporation	WEB SITE CDMO Business Information	✓					✓		A2 Healthcare Corporation
REPROCELL Inc.	CDMO Business Information	✓					✓		BioBridge Global、Histocell、Texcell
Ricoh Biosciences, K.K.	WEB SITE WEB SITE				✓			✓
Rohto Cell Factory Tokyo Co., Ltd.	CDMO Business Information	✓					✓
ROHTO Pharmaceutical Co., Ltd.	CDMO Business Information	✓ / Facilities under construction				✓	✓
S-RACMO Co.,Ltd.	WEB SITE CDMO Business Information	✓ / Facilities under construction				✓
Synplogen Co., Ltd.	WEB SITE CDMO Business Information		✓	✓	✓				Viral Vectors : Taiyo Pharma Tech Co., Ltd., FUJIFILM Corporation, Merck Group Plasmid DNA : MicroBiopharm Japan Co., Ltd. mRNA : FUJIFILM Toyama Chemical Co., Ltd., ARCALIS, Inc.
TAIYO Pharma Tech Co., Ltd.	WEB SITE CDMO Business Information	✓	✓
Takara Bio Inc.	WEB SITE CDMO Business Information	✓	✓ / Facilities under construction	✓	✓ / Facilities under construction	✓	✓	✓
TEIJIN REGENET CO., LTD.	WEB SITE CDMO Business Information	✓ / Facilities under construction	✓ / Facilities under construction	✓ / Facilities under construction		✓	✓		We are building the “Kashiwanoha Regenerative Medicine Platform” in collaboration with the National Cancer Center, J-TEC and Mitsui Fudosan, supporting seeds technology holders in addressing challenges including clinical trial preparation. Through business partnerships with TFBS Bioscience Inc. and Mediridge Co., Ltd, both team support the supply of GMP-grade viral vectors and plasmids. By forming strategic alliances with overseas CDMOs such as National RESILIENCE, Inc (USA), Hilleman Laboratories (Singapore), and others, we are establishing a global collaborative framework.
TFBS Bioscience, LLC	WEB SITE		✓						■GMP manufacturing is available up to a commercial scale at the facility of a group company (TFBS Bioscience, Inc.) in Taiwan. ■Integrated viral vector and plasmid supply is available through the alliance with Teijin Regenet and MediRidge.
U-Medico Inc.	WEB SITE WEB SITE		✓						TAIYO Pharma Tech Co., Ltd. Takara Bio Inc.